{"filing":{"accession_number":"0001493152-26-034933","cik":"0001595353","ticker":"GLMD","company_name":"Galmed Pharmaceuticals Ltd.","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595353/000149315226034933/form6-k.htm"},"events":[{"id":20902,"run_id":18822,"accession_number":"0001493152-26-034933","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces a significant development milestone: Galmed's breakthrough in formulating Aramchol as an orally dispersible film (ODF) with enhanced CNS penetration (~300% increase) and bioavailability (~150% increase) for Parkinson's disease treatment. The announcement highlights a differentiated drug-delivery innovation addressing a major clinical challenge (dysphagia in 80% of PD patients) and positions the program as an \"ideal out-licensing candidate\" in a $6+ billion market. While not a discrete M\u0026A transaction, this represents material operational and strategic progress in product development that would affect a reasonable investor's assessment of the company's pipeline value and licensing prospects.","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":[{"id":20406,"accession_number":"0001493152-26-034933","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a significant development milestone: Galmed's breakthrough in formulating Aramchol as an orally dispersible film (ODF) with enhanced CNS penetration (~300% increase) and bioavailability (~150% increase) for Parkinson's disease treatment. The announcement highlights a differentiated drug-delivery innovation addressing a major clinical challenge (dysphagia in 80% of PD patients) and positions the program as an \"ideal out-licensing candidate\" in a $6+ billion market. While not a discrete M\u0026A transaction, this represents material operational and strategic progress in product development that would affect a reasonable investor's assessment of the company's pipeline value and licensing prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:20:39.155628+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20406,"accession_number":"0001493152-26-034933","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a significant development milestone: Galmed's breakthrough in formulating Aramchol as an orally dispersible film (ODF) with enhanced CNS penetration (~300% increase) and bioavailability (~150% increase) for Parkinson's disease treatment. The announcement highlights a differentiated drug-delivery innovation addressing a major clinical challenge (dysphagia in 80% of PD patients) and positions the program as an \"ideal out-licensing candidate\" in a $6+ billion market. While not a discrete M\u0026A transaction, this represents material operational and strategic progress in product development that would affect a reasonable investor's assessment of the company's pipeline value and licensing prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T11:20:39.155628+00:00","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-07-28"}]}